Revvity, Inc. (NYSE: RVTY) shares slid $2.72 Tuesday, on the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, the heart of the state’s Research Triangle.
Reportedly, the center consolidates Revvity’s expertise and resources to drive R&D innovation and create the next generation of imaging systems backed by AI software tools and other advanced technologies.
The new facility is staffed by R&D teams from across the organization, including software, hardware, and applied biology/applications teams, as well as those specialized in machine learning, optical, microCT, and ultrasound.
Combined, these teams will help create opportunities and develop scientific solutions, addressing challenges in disease researchers’ workflows.
“The In Vivo Imaging Center of Excellence will allow Revvity to drive innovation at a faster pace and stay at the forefront of not only in vivo imaging, but also other imaging modalities shaping life sciences worldwide,” said Kevin Quick, vice president of platforms, life sciences.
The purpose of the site is to advance next-generation instruments, optical, x-ray CT, multi-modal AI analysis software, and ultrasound systems. Recent innovations in these fields from Revvity that are present at the site include the IVIS™ optical imaging systems*, Quantum™ GX3 microCT system*, Vega™ automated preclinical ultrasound system*, and the VivoJect™ Image-Guided Injection System* for targeted delivery of cells and therapies.
RVTY shares fell $2.72, or 3%, to $87.39.
